ArticleDrug design, development and therapy2018
Berberine nanoparticles with enhanced in vitro bioavailability: characterization and antimicrobial activity.
Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 153 citations in OpenAlex.
- Enhanced controlled drug delivery of berberine-loaded gelatin nanoparticles: characterization andRSC advances · 2026Article
- Therapeutic potential of zinc oxide/berberine nanoparticles in mitigating acute respiratory distress syndrome: in vivo and in silico approaches.BMC pharmacology & toxicology · 2025Article
- Article
- The delivery carriers and applications for Xiaobojian.Discover nano · 2025Review
- Molecular Evidence of the Bio-activities of Traditional Home Medicine Ingredients.Current topics in medicinal chemistry · 2025Review
- Research progress on pharmacological effects and bioavailability of berberine.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Characterization and antioxidant activity of nano-formulated berberine and cyperus rotundus extracts with anti-inflammatory effects in mastitis-induced rats.Scientific reports · 2024Article
- Improving the Antimicrobial Potency of Berberine for Endodontic Canal Irrigation Using Polymeric Nanoparticles.Pharmaceutics · 2024Article
- Bioactive Compounds from Plant Origin as Natural Antimicrobial Agents for the Treatment of Wound Infections.International journal of molecular sciences · 2024Review
- Article
- Recent Applications of Protoberberines as Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017-2023).ACS pharmacology & translational science · 2024Review
- Investigation of Antioxidant and Anti-inflammatory Properties of Berberine Nanomicelles:Current drug delivery · 2024Article
- Berberine HCl and diacerein loaded dual delivery transferosomes: Formulation and optimization using Box-Behnken design.ADMET & DMPK · 2024Article
- Development and evaluation of berberine-loaded bigel for the treatment of hyperpigmentation on B16F10 melanoma cell line.Nanomedicine (London, England) · 2024Article
- Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers.Pharmaceutics · 2023Article
- Article
- Elucidating Berberine's Therapeutic and Photosensitizer Potential through Nanomedicine Tools.Pharmaceutics · 2023Review
- Herbal Medicine Nanocrystals: A Potential Novel Therapeutic Strategy.Molecules (Basel, Switzerland) · 2023Review
- Fabrication of Co-Assembly from Berberine and Tannic Acid for Multidrug-Resistant Bacteria Infection Treatment.Pharmaceutics · 2023Article
- Thermodynamic Parameters of Berberine with Kolliphor Mixtures Adsorption and Micellization.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
- Retraction · 2024-02-02Concerns/Issues about Image · Duplication of/in Image · Investigation by Journal/Publisher · Original Data and/or Images not Provided and/or not Available · Unreliable Results and/or Conclusions · · https://pubpeer.com/publications/F3A9A414424CAF77C455B066705A9E
- Retracted
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBerberine is an isoquinoline alkaloid widely used in Ayurveda and traditional Chinese medicine to treat illnesses such as hypertension and inflammatory conditions, and as an anticancer and hepato-protective agent. Berberine has low oral bioavailability due to poor aqueous solubility and insufficient dissolution rate, which can reduce the efficacy of drugs taken orally. In this study, evaporative precipitation of nanosuspension (EPN) and anti-solvent precipitation with a syringe pump (APSP) were used to address the problems of solubility, dissolution rate and bioavailability of berberine.
methodsSemi-crystalline nanoparticles (NPs) of 90-110 nm diameter for APSP and 65-75 nm diameter for EPN were prepared and then characterized using differential scanning calorimetry (DSC) and X-ray powder diffractometry (XRD). Thereafter, drug content solubility and dissolution studies were undertaken. Berberine and its NPs were evaluated for their antibacterial activity.
resultsThe results indicate that the NPs have significantly increased solubility and dissolution rate due to conversion of the crystalline structure to a semi-crystalline form.
conclusionBerberine NPs produced by both APSP and EPN methods have shown promising activities against Gram-positive and Gram-negative bacteria, and yeasts, with NPs prepared through the EPN method showing superior results compared to those made with the APSP method and the unprocessed drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.